Key Insights

Highlights

Success Rate

83% trial completion

Published Results

26 trials with published results (20%)

Research Maturity

85 completed trials (65% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.8%

18 terminated out of 130 trials

Success Rate

82.5%

-4.0% vs benchmark

Late-Stage Pipeline

6%

8 trials in Phase 3/4

Results Transparency

31%

26 of 85 completed with results

Key Signals

26 with results83% success18 terminated

Data Visualizations

Phase Distribution

105Total
Not Applicable (21)
P 1 (62)
P 2 (14)
P 3 (6)
P 4 (2)

Trial Status

Completed85
Terminated18
Recruiting10
Unknown9
Not Yet Recruiting4
Enrolling By Invitation2

Trial Success Rate

82.5%

Benchmark: 86.5%

Based on 85 completed trials

Clinical Trials (130)

Showing 20 of 20 trials
NCT07563972Phase 1Not Yet Recruiting

Phase I Study of Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming in Advanced Solid Tumors

NCT07075185Phase 1Recruiting

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

NCT05909202Not ApplicableCompletedPrimary

A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients

NCT02154022Enrolling By Invitation

Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity

NCT04142567CompletedPrimary

Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation

NCT02851706Completed

Natural History of and Specimen Banking for People With Tumors of the Central Nervous System

NCT07447089Not ApplicableRecruiting

EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study

NCT06759649Phase 1RecruitingPrimary

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

NCT07192926Completed

Sarcopenia and CRP-TyG Index (CTI) as Predictors of Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer

NCT07405385Not ApplicableNot Yet Recruiting

Cardiotoxicity Assessment and Reduction Through Exercise in BREAST Cancer

NCT06739655Not ApplicableRecruiting

Preoperative Radiation Therapy and Immediate Breast Reconstruction

NCT05450562Phase 1TerminatedPrimary

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

NCT07314853Not ApplicableNot Yet RecruitingPrimary

Using Artificial Intelligence to Guide Fluid Therapy During Major Cancer Surgery: A Randomized Controlled Trial

NCT06782581Not ApplicableRecruitingPrimary

CARE Study: Cancer, Asian Americans, and Relationship Enrichment

NCT05013554Phase 1Terminated

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

NCT06980012Not ApplicableRecruitingPrimary

Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology.

NCT04717375Phase 1Terminated

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

NCT05101798Phase 2TerminatedPrimary

The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

NCT02354547Phase 1SuspendedPrimary

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

NCT03547037Phase 1CompletedPrimary

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

Scroll to load more

Research Network

Activity Timeline